We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.50 | 0.28% | 1,640.50 | 1,640.00 | 1,640.50 | 1,656.00 | 1,635.00 | 1,642.00 | 5,918,777 | 16:29:57 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.71 | 67.54B |
From Apr 2019 to Apr 2024
LONDON--U.K. drugmaker GlaxoSmithKline PLC (GSK.LN) Monday publicized positive results from a late-stage study of a treatment for pulmonary arterial hypertension, a condition characterized by constriction of the blood vessels in the lungs.
The study of the effects of the ambrisentan and tadalafil drugs, carried out in collaboration with Gilead Sciences Inc. (GILD), showed that the combination therapy worked better than either drug administered on its own.
"The length of time before patients experienced clinical failure was significantly prolonged for those receiving first-line combination compared to monotherapy," GSK said.
The two companies now plan to seek regulatory approval for the combination therapy by submitting the study data to regulators in the U.S., European Union and elsewhere.
At 1309 GMT, GSK shares were down 24 pence or 1.66% at 1,424 pence.
Write to Ed Ballard at ed.ballard@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
